Literature DB >> 35279732

Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility.

Christian D Fankhauser1, Luca Afferi2, Sean P Stroup3, Nicholas R Rocco3, Kathleen Olson4, Aditya Bagrodia5, Fady Baky5, Walter Cazzaniga6, Erik Mayer6, David Nicol6, Ekrem Islamoglu7, Stephane de Vergie8, Ragheed Saoud9, Scott E Eggener9, Sebastiano Nazzani10, Nicola Nicolai10, Lee Hugar11, Wade J Sexton11, Deliu-Victor Matei12, Ottavio De Cobelli12, Joseph Cheaib13, Phillip M Pierorazio13, James Porter14, Thomas Hermanns15, Robert J Hamilton16, Andreas Hiester17, Peter Albers17, Noel Clarke18, Agostino Mattei2.   

Abstract

PURPOSE: To describe the perioperative safety, functional and immediate post-operative oncological outcomes of minimally invasive RPLND (miRPLND) for testis cancer.
METHODS: We performed a retrospective multi-centre cohort study on testis cancer patients treated with miRPLND from 16 institutions in eight countries. We measured clinician-reported outcomes stratified by indication. We performed logistic regression to identify predictors for maintained postoperative ejaculatory function.
RESULTS: Data for 457 men undergoing miRPLND were studied. miRPLND comprised laparoscopic (n = 56) or robotic (n = 401) miRPLND. Indications included pre-chemotherapy in 305 and post-chemotherapy in 152 men. The median retroperitoneal mass size was 32 mm and operative time 270 min. Intraoperative complications occurred in 20 (4%) and postoperative complications in 26 (6%). In multivariable regression, nerve sparing, and template resection improved ejaculatory function significantly (template vs bilateral resection [odds ratio (OR) 19.4, 95% confidence interval (CI) 6.5-75.6], nerve sparing vs non-nerve sparing [OR 5.9, 95% CI 2.3-16.1]). In 91 men treated with primary RPLND, nerve sparing and template resection, normal postoperative ejaculation was reported in 96%. During a median follow-up of 33 months, relapse was detected in 39 (9%) of which one with port site (< 1%), one with peritoneal recurrence and 10 (2%) with retroperitoneum recurrences.
CONCLUSION: The low proportion of complications or peritoneal recurrences and high proportion of men with normal postoperative ejaculatory function supports further miRPLND studies.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Germ cell tumours; RPLND; Retroperitoneal lymph node dissection; Robotic surgery; Testis cancer

Mesh:

Year:  2022        PMID: 35279732     DOI: 10.1007/s00345-022-03974-9

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  17 in total

1.  Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence.

Authors:  Nicola Nicolai; Rosalba Miceli; Andrea Necchi; Davide Biasoni; Mario Catanzaro; Angelo Milani; Luigi Piva; Giorgio Pizzocaro; Silvia Stagni; Tullio Torelli; Roberto Salvioni
Journal:  Eur Urol       Date:  2010-08-27       Impact factor: 20.096

2.  Reply by Authors.

Authors:  Antoin Douglawi; Adam Calaway; Isamu Tachibana; Marcelo Panizzutti Barboza; Ryan Speir; Timothy Masterson; Nabil Adra; Richard Foster; Lawrence Einhorn; Clint Cary
Journal:  J Urol       Date:  2020-04-24       Impact factor: 7.450

3.  Midline Extraperitoneal Approach to Retroperitoneal Lymph Node Dissection in Testicular Cancer: Minimizing Surgical Morbidity.

Authors:  Sumeet Syan-Bhanvadia; Soroush T Bazargani; Thomas G Clifford; Jie Cai; Gus Miranda; Siamak Daneshmand
Journal:  Eur Urol       Date:  2017-03-18       Impact factor: 20.096

4.  A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections.

Authors:  Paul Lloyd; Anne Hong; Marc A Furrer; Elaine W Y Lee; Harveer S Dev; Maurice H Coret; James M Adshead; Peter Baldwin; Richard Knight; Jonathan Shamash; Constantine Alifrangis; Sara Stoneham; Danish Mazhar; Han Wong; Anne Warren; Ben Tran; Nathan Lawrentschuk; David E Neal; Benjamin C Thomas
Journal:  World J Urol       Date:  2021-10-01       Impact factor: 4.226

5.  Lymph node count impacts survival following post-chemotherapy retroperitoneal lymphadenectomy for non-seminomatous testicular cancer: a population-based analysis.

Authors:  Raj R Bhanvadia; Joseph Rodriguez; Aditya Bagrodia; Scott E Eggener
Journal:  BJU Int       Date:  2019-06-02       Impact factor: 5.588

6.  Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group.

Authors:  Axel Gerdtsson; Ulf Håkansson; Magnus Törnblom; George Jancke; Helene F S Negaard; Ingrid Glimelius; Dag Halvorsen; Ása Karlsdóttir; Hege Sagstuen Haugnes; Kristine Engen Andreassen; Signe Melsen Larsen; Göran Holmberg; Rolf Wahlqvist; Torgrim Tandstad; Gabriella Cohn-Cedermark; Olof Ståhl; Anders Kjellman
Journal:  Eur Urol Oncol       Date:  2019-09-08

7.  Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer.

Authors:  Jakob Lauritsen; Merete Kjaer Hansen; Mikkel Bandak; Michael Bay Kreiberg; Julie Wang Skøtt; Thomas Wagner; Maria Gry Gundgaard Kier; Niels Vilstrup Holm; Mads Agerbæk; Ramneek Gupta; Christian Dehlendorff; Klaus Kae Andersen; Gedske Daugaard
Journal:  J Clin Oncol       Date:  2019-12-10       Impact factor: 44.544

8.  Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study.

Authors:  Nilofer S Azad; Robert J Gray; Michael J Overman; Jonathan D Schoenfeld; Edith P Mitchell; James A Zwiebel; Elad Sharon; Howard Streicher; Shuli Li; Lisa M McShane; Larry Rubinstein; David R Patton; P Mickey Williams; Brent Coffey; Stanley R Hamilton; Nathan Bahary; J Marie Suga; Hassan Hatoum; Jeffrey S Abrams; Barbara A Conley; Carlos L Arteaga; Lyndsay Harris; Peter J O'Dwyer; Alice P Chen; Keith T Flaherty
Journal:  J Clin Oncol       Date:  2019-11-25       Impact factor: 50.717

9.  Outcomes of Postchemotherapy Retroperitoneal Lymph Node Dissection from a High-volume UK Centre Compared with a National Data Set.

Authors:  Adam Kieran Pearce; David Manson-Bahr; Alison Reid; Robert Huddart; Erik Mayer; David L Nicol
Journal:  Eur Urol Open Sci       Date:  2021-09-30

Review 10.  Major complications of post-chemotherapy retroperitoneal lymph node dissection in a contemporary cohort of patients with testicular cancer and a review of the literature.

Authors:  Christian Guido Ruf; Simon Krampe; Cord Matthies; Petra Anheuser; Tim Nestler; Jörg Simon; Hendrik Isbarn; Klaus Peter Dieckmann
Journal:  World J Surg Oncol       Date:  2020-09-24       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.